The Cascade of Pathophysiological Dysfunction in Duchenne Muscular Dystrophy

Written by Margaret Anne Rockwood | Last updated June 3rd, 2026
Medically reviewed by Jonathan Soslow, MD

Duchenne muscular dystrophy (DMD) is a severe X-linked recessive neuromuscular disorder characterized by progressive skeletal muscle degeneration, cardiomyopathy, respiratory failure, and premature mortality.

The disease is caused by mutations in the DMD gene—the largest known human gene—which encodes dystrophin, a large cytoskeletal protein essential for maintaining sarcolemmal integrity. The absence of dystrophin initiates a cascade of molecular and cellular events that culminate in progressive myofiber loss and replacement with fibrofatty tissue.

Steps from Origin to Dysfunction in DMD

A simplified flowchart of this cascade is helpful, although many of these dysfunctional mechanisms occur concurrently rather than strictly sequentially:

Dystrophin loss → sarcolemmal fragility → calcium dysregulation → myofiber injury → chronic inflammation → mitochondrial dysfunction + oxidative stress → failed regeneration → fibrosis/fatty replacement → skeletal muscle, cardiac, and vascular involvement → cardiopulmonary failure

This pathway creates a cycle of damage, repair, and eventual degeneration.

1. Primary Molecular Defect: Dystrophin Loss

In DMD, mutations are most commonly frameshift deletions of exons within the DMD gene. These mutations disrupt the reading frame, resulting in absent or severely truncated dystrophin protein.

Dystrophin is a critical component of the dystrophin-associated glycoprotein complex (DGC), which links intracellular actin filaments to the extracellular matrix through the sarcolemma. This structural linkage stabilizes the muscle membrane during contraction and helps preserve both mechanical integrity and proper signaling.

The DGC also has multiple cell-signaling roles, including binding of neuronal nitric oxide synthase (nNOS). This reduces vasodilation during muscle activity and contributes to functional ischemia.

2. Sarcolemmal Fragility

Without dystrophin, muscle fibers become mechanically fragile and highly susceptible to contraction-induced injury.

Repeated cycles of muscle contraction cause the sarcolemmal membrane to be unstable, unable to withstand normal contractile stress. This, in turn, produces sarcolemmal microtears and increased membrane permeability. This fragility allows abnormal ion movement across the membrane, particularly excessive calcium entry, into the myofiber.

The repetition of these injuries—rather than dystrophin deficiency alone—drive downstream processes such as chronic inflammation and fibrosis.

3. Calcium Dysregulation and Toxicity

The excessive calcium influx into muscle fibers activates calcium-dependent proteases such as calpains. These proteases degrade cytoskeletal proteins, myofibrillar proteins, and components of the contractile apparatus, further weakening structural integrity and impairing force generation.

Calcium overload also disrupts mitochondrial homeostasis, impairs ATP production, and causes mitochondrial dysfunction. This contributes to progressive myofibrillar degradation and primarily drives myofiber necrosis, with some contribution from apoptotic pathways.

4. Myofiber Injury and Necrosis

The combination of proteolytic damage, calcium toxicity, and mitochondrial dysfunction results primarily in myofiber necrosis.

Damaged fibers lose contractile function and eventually rupture, releasing intracellular contents that trigger immune activation. Progressive cycles of myonecrosis drive the clinical muscle weakness seen in DMD.

Necrosis—not apoptosis—is the dominant mechanism of muscle fiber loss in dystrophin-deficient muscle.

5. Chronic Inflammation and Immune Activation

Muscle fiber necrosis triggers infiltration of macrophages, T lymphocytes, and other immune cells. While acute inflammation can facilitate debris clearance in healthy systems, the persistent injury in DMD causes inflammation to become chronic and maladaptive.

Pro-inflammatory cytokines such as TNF-α and IL-6, along with activation of NF-κB signaling pathways, perpetuate tissue damage and impair regeneration.

At the same time, chronic inflammation stimulates pro-fibrotic pathways, particularly TGF-β signaling, which strongly drives fibrosis and disease progression.

6. Mitochondrial Dysfunction and Oxidative Stress

Dystrophin deficiency contributes significantly to mitochondrial dysfunction, primarily through calcium overload and disrupted membrane signaling.

Excess intracellular calcium impairs mitochondrial respiration, reduces ATP production, and increases the generation of reactive oxygen species (ROS).

Oxidative stress damages lipids, proteins, and DNA. It also amplifies membrane instability, impairs repair mechanisms, and worsens calcium-mediated injury. These processes reinforce one another, accelerating muscle degeneration.

7. Impaired Regeneration and Satellite Cell Dysfunction

Skeletal muscle normally repairs itself through activation of satellite cells, the resident muscle stem cells responsible for regeneration.

Dystrophin is important not only in mature muscle fibers but also in satellite cells, where it helps maintain cell polarity and supports asymmetric division during regeneration.

Because DMD causes repeated cycles of degeneration and regeneration, satellite cells require continuous activation. Over time, these cycles exhaust satellite cell function, while the absence of dystrophin weakens their regenerative capacity.

Satellite cell exhaustion limits the ability of muscle to regenerate after injury, leading to irreversible loss of muscle mass over time.

8. Fibrosis and Fatty Replacement

As regenerative capacity declines, muscle tissue is increasingly replaced by excessive extracellular matrix deposition in the form of fibrotic and adipose tissue.

Persistent muscle damage triggers pro-fibrotic cytokines, especially TGF-β (transforming growth factor-beta), which activates fibroblasts and promotes collagen deposition.

Fibro-adipogenic progenitors (FAPs), which normally support transient repair, expand under chronic inflammatory conditions. In the presence of persistent TGF-β signaling, these cells differentiate into fibroblasts that drive fibrosis and adipocytes that contribute to fatty infiltration.

At the same time, exhausted satellite cells can no longer regenerate functional myofibers effectively, shifting muscle repair toward a replacement model dominated by fibrofatty tissue.

Fibrosis is a central driver of disease progression. Skeletal muscle fibrosis occurs early, while cardiac fibrosis develops progressively and correlates strongly with clinical outcomes.

9. Skeletal, Cardiac and Vascular Dysfunction

This complex cascade affects skeletal and cardiac muscle and also leads to vascular smooth muscle dysfunction. When cardiac muscle is affected by dystrophin deficiency, it may lead to progressive myocardial injury, fibrosis, ventricular remodeling, dilated cardiomyopathy, and arrhythmias.

10. Cardiopulmonary Failure

Cardiopulmonary failure is the major cause of morbidity and mortality in DMD. Progressive myocardial fibrosis, impaired contractility, arrhythmias, and ventricular dilation eventually lead to heart failure. With the improvement in respiratory care, particularly through the use of non-invasive and invasive ventilation, cardiovascular disease has become the leading cause of death.

Epigenetic Dysregulation and HDAC Activity

In addition to structural and inflammatory mechanisms, DMD progression is influenced by epigenetic dysregulation.

Histone deacetylases (HDACs) are enzymes that modify chromatin structure and suppress gene transcription by removing acetyl groups from histones. In DMD, HDAC activity is upregulated, contributing to impaired muscle regeneration and disease progression. Increased HDAC activity suppresses the expression of myogenic regulatory factors necessary for satellite cell differentiation, thereby limiting effective muscle repair.

HDACs also interact with pro-fibrotic signaling pathways such as TGF-β, promoting fibroblast activation and extracellular matrix deposition. Additionally, chronic inflammation further enhances HDAC activity, creating a feedback loop that reinforces pathological gene expression.

These mechanisms position HDACs as key modulators linking inflammation, failed regeneration, and fibrosis in DMD.

Neuromuscular Junction and CNS Effects

Dystrophin is also expressed in the brain and at the neuromuscular junction (NMJ). Its absence can alter synaptic signaling and neuronal communication, contributing to subtle cognitive impairment, learning difficulties, and behavioral abnormalities observed in some patients with DMD.

Although skeletal and cardiac muscle disease dominate clinically, these neurological effects are increasingly recognized as important components of the disorder.

The State of Current Research

Recent research in DMD has focused heavily on therapies that target both the primary genetic defect and the downstream pathological pathways.

Current strategies include exon-skipping therapies, micro-dystrophin gene therapy, CRISPR-based gene editing, and corticosteroid alternatives. Additional research targets inflammation, fibrosis, oxidative stress, HDAC signaling, and mitochondrial dysfunction to preserve muscle function even when full dystrophin restoration is not possible.

Understanding the molecular pathophysiology of DMD provides the foundation for these emerging therapies and highlights why successful treatment likely requires both genetic correction and downstream pathway modulation.

References

1. Role of Ca²⁺, ROS, and nitric oxide in dystrophin-deficient muscle. Allen, D. G., Whitehead, N. P., & Froehner, S. C. (2016). Physiological Reviews, 96(1), 253–305.
2. Satellite cells and skeletal muscle regeneration. Dumont, N. A., et al. (2015). Comprehensive Physiology, 5(3), 1027–1059.
3. Histone deacetylase inhibition with givinostat. Aartsma-Rus, A. (2025). Drug Discovery Today, 30(2), 104241.
4. Muscle injury activates fibro/adipogenic progenitors. Joe, A. W. B., et al. (2010). Nature Cell Biology, 12(2), 153–163.
5. Cloning of the DMD gene. Koenig, M., et al. (1987). Cell, 50(3), 509–517.
6. Skeletal muscle fibrosis overview. Mahdy, M. A. A. (2019). Cell and Tissue Research, 375(3), 575–588.
7. Duchenne muscular dystrophy. Duan, D., et al. (2021). Nature Reviews Disease Primers, 7(1), 13.
8. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Minetti, G. C., et al. (2006). Nature Medicine, 12(10), 1147–1150.
9. Absence of dystrophin disrupts skeletal muscle signaling: Roles of Ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy. Allen, D. G., Whitehead, N. P., & Froehner, S. C. (2016). Physiological Reviews, 96(1), 253–305.
10. Regulation of muscle growth and regeneration by the immune system. Tidball, J. G. (2017). Nature Reviews Immunology, 17(3), 165–178.
11. Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the imbalance between utrophin and dystrophin in Duchenne muscular dystrophy. Timpani, C. A., Hayes, A., & Rybalka, E. (2017). FEBS Journal.
12. Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update. Sun, C., et al. (2020). Genes (Basel), 11(8), 837.
13. Muscle injury activates fibro/adipogenic progenitors. Joe, A. W. B., et al. (2010). Nature Cell Biology, 12(2), 153–163.